Apr 18, 2014 at 14:32 | Source: Reuters
Medicines produced in India, which supplies about 40 percent of generic and over-the-counter drugs sold in the United States, have come under increased scrutiny by the Food and Drug Administration over the past year.
Apr 18, 2014 at 09:45 | Source: Moneycontrol.com
In the technology space, Infosys advanced 0.57 percent to USD 52.88 while Wipro fell 0.73 percent to USD 13.61.
Apr 17, 2014 at 08:23 | Source: Moneycontrol.com
Indian ADRs ended mixed on Wednesday. Dr Reddy's Laboratories shed 1.61 percent and Tata Motors advanced 2 percent.
Apr 16, 2014 at 11:00 | Source: Moneycontrol.com
Infosys, TCS, Wipro, Cipla and Dr Reddy's Labs are laggards in the Sensex. Among the gainers are Hindalco, ITC, Maruti, Tata Steel and ICICI Bank.
Apr 16, 2014 at 10:18 | Source: Moneycontrol.com
Dr Reddys Laboratories has launched Eszopiclone Tablets (C-IV) 1 mg, 2 mg and 3 mg, a therapeutic equivalent generic version of LUNESTA tablets C-IV in the US market on April 15, 2014, following the approval by the USFDA.
Apr 16, 2014 at 08:28 | Source: Moneycontrol.com
Indian ADRs ended mostly lower on Tuesday. Wipro gained more than 2 percent, while Infosys plunged 4.68 percent.
Apr 15, 2014 at 14:16 | Source: Reuters
The Suprax recall is the second for India's fourth-largest drugmaker by sales, after pulling nearly 65,000 bottles from the US in January last year because of discoloration.
Apr 15, 2014 at 11:02 | Source: Moneycontrol.com
Wipro, Bharti Airtel, TCS and Dr Reddys Labs are top gainers in the Sensex. Among the laggards are HDFC, Tata Motors, Hindalco, M&M and Hero Motocorp.
Apr 15, 2014 at 08:23 | Source: Moneycontrol.com
Indian ADRs ended higher on Monday. ICICI Bank jumped 1.41 percent and Infosys rose 4.57 percent.
Apr 12, 2014 at 13:21 | Source: CNBC-TV18
Tirthankar Patnaik, Director at Institutional Research, Religare Capital Markets recommends buying Infosys from the IT pack. He is overweight on IT and pharma.